AMPH

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company founded in 1996 and headquartered in Rancho Cucamonga, California. The company went public in 2014 and has evolved from a generic drug manufacturer into a diversified pharmaceutical company focused on injectable, inhalation, and intranasal products. Amphastar operates through two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API), serving hospitals, care facilities, clinics, and doctors' offices primarily in the United States, with additional operations in China and France. The company has built a vertically integrated business model, manufacturing 100% of its products domestically, which provides both cost control and supply chain security advantages.